Loading company…
Copenhagen biotech developing CRISPR-based therapies that selectively eliminate harmful bacteria from the microbiome.
Based in Copenhagen, Denmark, Snipr Biome Aps was co-founded in 2011 by Christian Grøndahl (CEO), Morten O. A. Sommer (Chair of Research) and Jasper Clube (Chief Intellectual Property Officer). It uses CRISPR/Cas technology to selectively remove target bacteria while sparing beneficial microbiota, aiming at inflammatory bowel disease, drug-resistant infections and cancer. Its pipeline includes SNIPR001-Oral, SNIPR-IV and SNIPR T2D/Obesity. In July 2025 it raised EUR 35 million in Series B funding from SPRIND, Cystic Fibrosis Foundation, Lundbeckfond Ventures, Wellington Partners and North-East Venture.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in